echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > JEM Fu Yangxin/Peng Hua collaborated to develop a new generation of tumor-specific anti-PD-1-IL-15 immunotherapy drugs

    JEM Fu Yangxin/Peng Hua collaborated to develop a new generation of tumor-specific anti-PD-1-IL-15 immunotherapy drugs

    • Last Update: 2022-10-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    As a new method of tumor treatment that has developed rapidly in recent years, tumor immunotherapy has made the situation of tumor treatment look new by mobilizing the body's own immune system to fight tumors




    https://doi.




    Reprint Notice

    【Non-original article】The copyright of this article belongs to the author of the article, welcome individuals to forward and share, without the author's permission is prohibited from reprinting, the author has all legal rights, violators will be prosecuted



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.